Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Deals of the Week: Is Botox On The Block?

Executive Summary

A pair of setbacks have sent Allergan’s stock price south, but will a buyer take advantage and buy it in a mega-deal? Also, Amgen and Servier team up in a CV deal, Forma pursues an asset-focused strategy in tandem with Cancer Research Technology, and Immunocore reveals an antibody deal with GSK.

You may also be interested in...

Double-Jointed Partnership With Servier Could Jumpstart Amgen’s CV Portfolio

Amgen gets U.S. rights to a pair of heart failure candidates from the French firm, with the lead candidate already approved in Europe and likely to be filed quickly at FDA. Meanwhile, Servier obtains EU commercialization rights to a CV drug partnered between Amgen and Cytokinetics.

uniQure Grants Chiesi Select Commercial Rights For The EU’s First Approved Gene Therapy Glybera And Hemo B Gene Therapy

uniQure has licensed commercial rights covering Europe and select emerging markets to Italy’s Chiesi for first-to-market gene therapy Glybera and a developmental hemophilia B product. The Dutch biopharma is writing the book on pricing and commercialization, regulatory approval, and market access strategy for gene therapy.

Forma To Rev Its Discovery Engine For Deubiquitination

In a new collaboration with Cancer Research Technology, drug-discovery firm Forma Therapeutics adds another area of cancer biology – and another unusual deal structure – to its panoply of partnerships.

Related Content


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts